Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tight controls and focus on innovation provide strong outlook for Roche

This article was originally published in Scrip

Executive Summary

Taking Roche on the road to present its financial results is developing into a habit for CEO Severin Schwan, who brought his top team to London again on July 23rd to unveil another impressive performance from the world’s number five in pharma in ex-factory sales and clear number one in diagnostics.

You may also be interested in...



Biosecurity Centre And ‘Test And Trace’ To Augment UK’s COVID-19 Test Momentum

The UK has added important new capabilities to its COVID-19 monitoring and control effort and those running it promise a “world class system” by late summer.

Fact File: European COVID-19 Focus Shifts To Managing The ‘New Normal’

The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.

Change Is Coming In Health Care, If Not Yet At The Speeds Of Other Consumer Industries

The advent of COVID-19 and its effects on care delivery have meant that short-term priorities for health care systems have switched temporarily to public health emergency mode. But the longer-term need to restructure delivery around outcomes and federated data management for patients is here to stay, says Royal Philips’ Jeroen Tas.

Topics

Related Companies

UsernamePublicRestriction

Register

PL043173

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel